You have matched to 1 trial

Guest Profile:  No profile selected

Copy link
Sort by zip code: 94107 Hide Map Icon
NCT05933265
Clear All Filters
mail-icon

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.
1

LP-184 Chemotherapy for Advanced Triple Negative Breast Cancer or Breast Cancer with DNA Damage Mutations

A Phase 1/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients with Advanced or Metastatic Solid Tumors

Purpose: To study the safety, best dose, and effects (good and bad) of LP-184, an experimental chemotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer or breast cancer with a DNA damage mutation who have no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following:

  • LP-184, by IV, weekly, 2 weeks on, 1 week off

What's being studied?

  • LP-184 is an experimental chemotherapy drug causing tumor cell death through DNA damage.
  • DNA damage mutations may include BRCA1, BRCA2, PALB2, ATM, CHEK2, and others.
  • This trial is also enrolling people with other types of cancer.

How can I learn more?

1

LP-184 Chemotherapy for Advanced Triple Negative Breast Cancer or Breast Cancer with DNA Damage Mutations

A Phase 1/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients with Advanced or Metastatic Solid Tumors
Icon

Nearest Location:
366 miles
Cancer and Blood Specialty Clinic
Los Alamitos, CA

Icon

Visits:
1 visit every 1-2 weeks

Icon

ClinicalTrials.gov: NCT05933265

Icon

Phase I-II

HELP GUIDE
HELP GUIDE
BESbswy